摘要
随着对脂蛋白(a) [Lp(a)]的研究不断进展,Lp(a)已成为公认的增加心血管事件风险的独立危险因素。近期的研究表明,低密度脂蛋白水平达标的情况下仍会有心血管事件发生,这意味着有其他的危险因素作用于心血管疾病,也称为残余风险。本文旨在阐述Lp(a)与动脉粥样硬化性心血管疾病(Atherosclerotic Cardiovascular Disease, ASCVD)的研究进展和治疗血浆Lp(a)升高的药物进展。
As the progress of lipoprotein(a) research, Lp(a) has become acknowledged an independent risk factor that affects cardiovascular disease. Recent studies have shown that regulating levels of low-density lipoprotein cholesterol (LDL-C) cannot fully control disease, suggesting there are other factors contributing to the risk of cardiovascular disease, which is named residual risks. This review aims to introduce the research progress between Lp(a) and ASCVD and the research progress of Lp(a) treatment methods.
出处
《临床医学进展》
2022年第12期11051-11056,共6页
Advances in Clinical Medicine
